BioSpace News Archive

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced financial results for the three months ended June 30, 2020.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended June 30, 2020.

GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020.

Luminex Corporation (Nasdaq: LMNX) today announced results for its second quarter ended June 30, 2020.

Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, today announced that it has received a 510(k) clearance from the FDA for its Bioflux Software II System. The software is engineered to improve workflows and reduce analysis time from 5 minutes to 30 seconds. ECG monitoring requires significant human oversight to review and interpret incoming patient data to discern actionable events

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, announced the pre-launch introduction of its new HTG EdgeSeq Reveal RUO oncology applications, which are expected to be commercially available globally in late August with the release of HTG EdgeSeq Reveal version 3.0.

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with The Uniformed Services University of the Health Sciences (“USU”), an institution of higher learning within the United States Department of Defense (DoD), and The Henry M. Jackson Foundat

Brilacidin is showing consistent and robust antiviral activity across the viral lifecycle in human lung and Vero cells; potential as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected

MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI”), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11 th ,

Astellas Pharma US, Inc. announced the call for entries for the Astellas Oncology C3 Prize, a global challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones.